Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488793 | 1.00 | EGFR (0.51) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL690318 | 0.78 | TGM2 (0.71) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL691250 | 0.77 | MEN1 (0.56) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL691113 | 0.77 | EGFR (0.67) | EGFRERBB3ERBB2BTKKCNH2 | |
| SCHEMBL16158635 | 0.75 | EGFR (0.58) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL691633 | 0.75 | EGFR (0.47) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL691637 | 0.75 | EGFR (0.60) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL3487003 | 0.74 | MEN1 (0.61) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL691983 | 0.74 | EGFR (0.48) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL691980 | 0.74 | EGFR (0.48) | EGFRERBB3MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016296-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885ERBB3 294/4885MEN1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.